Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India’s Ranbaxy, Three Other Generics Named In Buy-Off Suit By U.S. FTC

This article was originally published in PharmAsia News

Executive Summary

Ranbaxy Pharmaceuticals of India has been named among four companies Cephalon is alleged to have paid to delay marketing a generic version of the American company's Provigil (modafinil) narcolepsy drug. The suit was filed in the U.S. District Court in Washington for the Federal Trade Commission, which said Cephalon had acted to protect a drug worth $800 million in annual sales. Besides Ranbaxy, which did not comment on the suit, other drug makers accused of providing $200 million worth of inducements were Barr Pharmaceuticals, Mylan Pharmaceuticals and Teva Pharmaceutical Industries. (Click here for more - a subscription may be required )

You may also be interested in...



Asia Executives On The Move: Sanofi's Global R&D Head Moves To Innovent

Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.

Woodcock's Prophesy Comes True: US FDA ANDA Approvals Decline From Record Levels

Janet Woodcock’s 2019 prediction that record ANDA approval volumes would not continue is confirmed with the FY 2020 approval total down 21% from the previous year.

Endo Brings All Xiaflex Revenue In House With BioSpecifics Acquisition

Deal snapshot: Resolving a loose end from its 2014 buyout of Auxilium, Endo acquires all rights to Xiaflex, along with approved cellulite therapy Qwo.

UsernamePublicRestriction

Register

LL1133148

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel